<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01486199</url>
  </required_header>
  <id_info>
    <org_study_id>1R01HL108929-01</org_study_id>
    <secondary_id>R01HL108929</secondary_id>
    <nct_id>NCT01486199</nct_id>
  </id_info>
  <brief_title>Imaging Airway Liquid Absorption in Cystic Fibrosis</brief_title>
  <official_title>Imaging Airway Liquid Absorption in Cystic Fibrosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Pittsburgh</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institutes of Health (NIH)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Heart, Lung, and Blood Institute (NHLBI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Pittsburgh</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators are developing a new nuclear medicine imaging technique for measuring
      liquid absorption in the airways that can be applied to screen new medications being
      developed to treat cystic fibrosis (CF). The investigators believe that the absorption of the
      small molecule radiopharmaceutical Indium 111-diethylenetriaminepentaacetic acid (In-DTPA)
      will indicate changes in liquid absorption in the airways and demonstrate whether new CF
      medications will be effective. In this study the investigators will further develop this
      technique through testing involving pediatric CF patients and healthy control subjects.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The investigators have recently developed a novel aerosol-based imaging technique to detect
      changes in liquid absorption in the airways - a central pathophysiological process known to
      be important in cystic fibrosis (CF) lung disease. This technique may provide a measure of
      disease severity and indication of therapeutic correction in advance of currently available
      outcome measures. It involves the simultaneous delivery of two radiopharmaceuticals by
      inhalation: one an absorbable small-molecule (Indium-111 labeled
      diethylenetriaminepentaacetic acid; In-DTPA) and the other a non-absorbable particle
      (Technetium 99m labeled sulfur colloid; Tc-SC). The overarching hypothesis is that In-DTPA
      absorption provides a quantifiable, non-invasive measurement of airway liquid absorption that
      (a) is sensitive to CF genotype, (b) uniquely identifies basic disease phenotype and predicts
      disease severity, and (c) is modulated by therapeutic interventions.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2011</start_date>
  <completion_date type="Actual">October 2014</completion_date>
  <primary_completion_date type="Actual">October 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Absorptive Clearance Rate</measure>
    <time_frame>study day 1</time_frame>
    <description>Absorptive clearance rate measured 80 minutes after radiopharmaceutical inhalation. Absorptive clearance is the absorptive component of the clearance of Indium 111-diethylenetriaminepentaacetic acid (In-DTPA) from the lungs.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Mucociliary Clearance Rate</measure>
    <time_frame>study day 1</time_frame>
    <description>Mucociliary clearance rate measured 80 minutes after radiopharmaceutical inhalation. Mucociliary clearance rate is the rate of clearance of Technetium sulfur colloid (Tc-SC) from the lungs.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Absorptive Clearance Rate</measure>
    <time_frame>t=2 years</time_frame>
    <description>Absorptive Clearance Rate measured 80 minutes after radiopharmaceutical inhalation. Absorptive clearance is the absorptive component of the clearance of In-DTPA from the lungs.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mucociliary Clearance Rate</measure>
    <time_frame>t=2 years, measure made 80 minutes after radiopharmaceutical inhalation</time_frame>
    <description>Mucociliary clearance rate measured 80 minutes after radiopharmaceutical inhalation. Mucociliary clearance rate is the rate of clearance of Technetium sulfur colloid (Tc-SC) from the lungs.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Cystic Fibrosis</condition>
  <arm_group>
    <arm_group_label>CF pediatric</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In the pediatric arm 10 CF subjects ages 6-14 will perform absorptive clearance scans at baseline and at t=2 years.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Controls adult</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In the adult control arm 10 healthy adult subjects will perform a single absorptive clearance scan.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Absorptive clearance scan</intervention_name>
    <description>Subjects will inhale a nebulized mixture of the radiopharmaceuticals Indium 111-DTPA and Technetium 99m-sulfur colloid.</description>
    <arm_group_label>CF pediatric</arm_group_label>
    <arm_group_label>Controls adult</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adult healthy control arm:

               -  subjects 18 years old or older without a diagnosis of lung disease.

          -  Pediatric CF arm:

               -  subjects 6-14 years with a diagnosis of cystic fibrosis as determined by sweat
                  test or genotype

               -  subjects who are clinically stable as determined by the pediatrician
                  co-investigator

               -  subjects must have a previously demonstrated ability to perform reproducible
                  pulmonary function testing based on previous clinical visits.

          -  Females in all groups who are of child-bearing potential will need to have a negative
             urine pregnancy test.

        Exclusion Criteria:

          -  Adult healthy control arm:

               -  FEV1%p &lt; 80% of predicted

               -  nursing mother

               -  positive urine pregnancy test or unwilling to test

               -  cigarette smoker (regular smoking within 6 months of study).

          -  Pediatric CF arm:

               -  FEV1%p &lt; 40% of predicted

               -  nursing mother

               -  positive urine pregnancy test for females of childbearing potential

               -  unable or unwilling to comply with test procedure

               -  cigarette smoker (regular smoking within 6 months of study).

               -  Subjects unable to lie recumbent without moving for the 80 minute imaging period
                  will be excluded.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tim Corcoran, Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Pittsburgh</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Pittsburgh</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.dom.pitt.edu/paccm/faculty_info.aspx/Corcoran5127</url>
    <description>Dr. Corcoran's University Webpage</description>
  </link>
  <verification_date>July 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 18, 2011</study_first_submitted>
  <study_first_submitted_qc>December 5, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 6, 2011</study_first_posted>
  <results_first_submitted>April 5, 2017</results_first_submitted>
  <results_first_submitted_qc>July 24, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">September 25, 2017</results_first_posted>
  <last_update_submitted>July 24, 2017</last_update_submitted>
  <last_update_submitted_qc>July 24, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">September 25, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Pittsburgh</investigator_affiliation>
    <investigator_full_name>Tim Corcoran</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <keyword>cystic fibrosis</keyword>
  <keyword>mucociliary clearance</keyword>
  <keyword>airway surface liquid</keyword>
  <keyword>nuclear medicine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fibrosis</mesh_term>
    <mesh_term>Cystic Fibrosis</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>CF Pediatric</title>
          <description>Cystic Fibrosis subjects ages 6-14</description>
        </group>
        <group group_id="P2">
          <title>Controls Adult</title>
          <description>Adult control subjects 18 or older</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Baseline Study Day</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Two Year Period Between Study Days</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Study Day at t= 2 Years</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>CF Pediatric</title>
          <description>Cystic Fibrosis subjects ages 6-14</description>
        </group>
        <group group_id="B2">
          <title>Controls Adult</title>
          <description>Adult control subjects 18 or older</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="10"/>
            <count group_id="B2" value="10"/>
            <count group_id="B3" value="20"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10.5" spread="1.5"/>
                    <measurement group_id="B2" value="31.2" spread="15.0"/>
                    <measurement group_id="B3" value="20.9" spread="14.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="9"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Absorptive Clearance Rate</title>
        <description>Absorptive clearance rate measured 80 minutes after radiopharmaceutical inhalation. Absorptive clearance is the absorptive component of the clearance of Indium 111-diethylenetriaminepentaacetic acid (In-DTPA) from the lungs.</description>
        <time_frame>study day 1</time_frame>
        <population>One pediatric subject did not deposit sufficient aerosol to be analyzed. One control subject did not perform imaging procedures after signing consent because of a low result on a screening pulmonary function testing.</population>
        <group_list>
          <group group_id="O1">
            <title>CF Pediatric</title>
            <description>CF subjects ages 6-14</description>
          </group>
          <group group_id="O2">
            <title>Controls Adult</title>
            <description>Adult control subjects 18 or older</description>
          </group>
        </group_list>
        <measure>
          <title>Absorptive Clearance Rate</title>
          <description>Absorptive clearance rate measured 80 minutes after radiopharmaceutical inhalation. Absorptive clearance is the absorptive component of the clearance of Indium 111-diethylenetriaminepentaacetic acid (In-DTPA) from the lungs.</description>
          <population>One pediatric subject did not deposit sufficient aerosol to be analyzed. One control subject did not perform imaging procedures after signing consent because of a low result on a screening pulmonary function testing.</population>
          <units>percent cleared / 80 minutes</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34.0" spread="10.4"/>
                    <measurement group_id="O2" value="17.7" spread="6.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Comparing absorptive clearance in CF children vs adult controls</groups_desc>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <non_inferiority_desc>alpha=0.05</non_inferiority_desc>
            <p_value>0.002</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Mucociliary Clearance Rate</title>
        <description>Mucociliary clearance rate measured 80 minutes after radiopharmaceutical inhalation. Mucociliary clearance rate is the rate of clearance of Technetium sulfur colloid (Tc-SC) from the lungs.</description>
        <time_frame>study day 1</time_frame>
        <population>One pediatric subject did not deposit sufficient aerosol to be analyzed. One control subject did not perform imaging procedures after signing consent because of a low result on a screening pulmonary function testing.</population>
        <group_list>
          <group group_id="O1">
            <title>CF Pediatric</title>
            <description>CF subjects ages 6-14</description>
          </group>
          <group group_id="O2">
            <title>Controls Adult</title>
            <description>Adult control subjects 18 or older</description>
          </group>
        </group_list>
        <measure>
          <title>Mucociliary Clearance Rate</title>
          <description>Mucociliary clearance rate measured 80 minutes after radiopharmaceutical inhalation. Mucociliary clearance rate is the rate of clearance of Technetium sulfur colloid (Tc-SC) from the lungs.</description>
          <population>One pediatric subject did not deposit sufficient aerosol to be analyzed. One control subject did not perform imaging procedures after signing consent because of a low result on a screening pulmonary function testing.</population>
          <units>percent cleared / 80 minutes</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.8" spread="13.7"/>
                    <measurement group_id="O2" value="31.4" spread="13.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Comparison of mucociliary clearance in CF children compared to healthy adults</groups_desc>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <non_inferiority_desc>alpha = 0.05</non_inferiority_desc>
            <p_value>0.20</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Absorptive Clearance Rate</title>
        <description>Absorptive Clearance Rate measured 80 minutes after radiopharmaceutical inhalation. Absorptive clearance is the absorptive component of the clearance of In-DTPA from the lungs.</description>
        <time_frame>t=2 years</time_frame>
        <population>Only pediatric CF subjects performed 2 year follow-up scan. One subject did not perform the second imaging day since day one image quality was poor. Two other subjects had poor imaging data on follow up day and were therefore not included in analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>CF Pediatric</title>
            <description>CF subjects ages 6-14</description>
          </group>
          <group group_id="O2">
            <title>Controls Adult</title>
            <description>Adult control subjects 18 or older</description>
          </group>
        </group_list>
        <measure>
          <title>Absorptive Clearance Rate</title>
          <description>Absorptive Clearance Rate measured 80 minutes after radiopharmaceutical inhalation. Absorptive clearance is the absorptive component of the clearance of In-DTPA from the lungs.</description>
          <population>Only pediatric CF subjects performed 2 year follow-up scan. One subject did not perform the second imaging day since day one image quality was poor. Two other subjects had poor imaging data on follow up day and were therefore not included in analysis.</population>
          <units>percent cleared / 80 min</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.6" spread="9.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Comparing absorptive clearance at t=0 vs t=2 years in pediatric CF subjects</groups_desc>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <non_inferiority_desc>alpha=0.05</non_inferiority_desc>
            <p_value>0.24</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mucociliary Clearance Rate</title>
        <description>Mucociliary clearance rate measured 80 minutes after radiopharmaceutical inhalation. Mucociliary clearance rate is the rate of clearance of Technetium sulfur colloid (Tc-SC) from the lungs.</description>
        <time_frame>t=2 years, measure made 80 minutes after radiopharmaceutical inhalation</time_frame>
        <population>Only pediatric CF subjects performed 2 year follow-up scan. One subject did not perform the second imaging day since day one image quality was poor. Two other subjects had poor imaging data on follow up day and were therefore not included in analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>CF Pediatric</title>
            <description>CF subjects ages 6-14</description>
          </group>
          <group group_id="O2">
            <title>Controls Adult</title>
            <description>Adult control subjects 18 or older</description>
          </group>
        </group_list>
        <measure>
          <title>Mucociliary Clearance Rate</title>
          <description>Mucociliary clearance rate measured 80 minutes after radiopharmaceutical inhalation. Mucociliary clearance rate is the rate of clearance of Technetium sulfur colloid (Tc-SC) from the lungs.</description>
          <population>Only pediatric CF subjects performed 2 year follow-up scan. One subject did not perform the second imaging day since day one image quality was poor. Two other subjects had poor imaging data on follow up day and were therefore not included in analysis.</population>
          <units>percent cleared / 80 minutes</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.0" spread="13.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Comparing mucociliary clearance at t=0 and t=2yrs in pediatric CF subjects</groups_desc>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <non_inferiority_desc>alpha=0.05</non_inferiority_desc>
            <p_value>0.87</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>CF Pediatric</title>
          <description>cystic fibrosis subjects ages 6-14</description>
        </group>
        <group group_id="E2">
          <title>Controls Adult</title>
          <description>adult controls 18 or older</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Tim Corcoran</name_or_title>
      <organization>University of Pittsburgh</organization>
      <phone>412-624-8918</phone>
      <email>corcorante@upmc.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

